Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts hold a “Moderate Buy” consensus on Omnicell, with seven buys, one hold and one sell among nine analysts. The average 12-month price target is $57.86, well above the stock’s reported $35.50 opening price.
• Recent analyst actions were mixed but generally cautious: Zacks downgraded Omnicell to “strong sell,” while KeyCorp, Piper Sandler and Wells Fargo maintained overweight ratings but lowered their price targets.
• Omnicell exceeded quarterly expectations with $0.94 in EPS versus $0.47 expected and revenue of $312.2 million, up 7.4% year over year. However, Zacks cut several near-term and 2027 earnings estimates, while institutional investors collectively own 97.7% of the stock.

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $57.8571.

OMCL has been the topic of several research analyst reports. Zacks Research cut Omnicell from a "hold" rating to a "strong sell" rating in a research note on Friday, August 7th. KeyCorp decreased their target price on Omnicell from $70.00 to $65.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Piper Sandler reiterated an "overweight" rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Wells Fargo & Company dropped their price target on Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Finally, Weiss Ratings upgraded Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dana Investment Advisors Inc. purchased a new stake in shares of Omnicell during the 4th quarter worth $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Omnicell by 71.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company's stock valued at $6,343,000 after purchasing an additional 58,193 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in Omnicell by 96.3% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company's stock valued at $1,174,000 after purchasing an additional 12,713 shares during the last quarter. Peregrine Capital Management LLC purchased a new position in Omnicell in the fourth quarter valued at about $4,804,000. Finally, Jackson Creek Investment Advisors LLC bought a new position in Omnicell in the fourth quarter worth about $2,022,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Down 2.6%

Shares of OMCL opened at $35.50 on Friday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 42.26, a PEG ratio of 0.91 and a beta of 0.98. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell has a 1-year low of $29.06 and a 1-year high of $55.00. The company has a 50-day moving average of $40.42 and a 200 day moving average of $39.71.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, research analysts expect that Omnicell will post 1.41 EPS for the current year.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks raised its FY2026 EPS estimate for Omnicell to $1.49 from $1.27, above the $1.30 consensus estimate. It also modestly increased its FY2028 forecast to $1.73 from $1.71, suggesting some longer-term earnings potential.
• Neutral Sentiment: The FY2026 estimate remains well below Omnicell’s stated full-year 2026 guidance of $2.15-$2.30 EPS, highlighting a significant disagreement between company expectations and the analyst’s forecast. The company’s latest reported quarter was stronger than expected, with $0.94 EPS and $312.2 million in revenue, but investors are focused on forward estimates.
• Negative Sentiment: Zacks reduced its Q3 2026 EPS estimate to $0.25 from $0.27 and sharply cut Q4 2026 EPS to $0.07 from $0.31. It also lowered Q1 2027 EPS to $0.25 from $0.31, Q2 2027 EPS to $0.23 from $0.32, Q3 2027 EPS to $0.32 from $0.33, and FY2027 EPS to $1.27 from $1.34. These cuts imply weaker near-term profitability and are likely the primary reason for the negative market sentiment. Zacks Research Has Negative Outlook for Omnicell Q1 Earnings

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source